The preclinical study of a new nasal spray with the anti-inflammatory properties: the effect on the leukotriene-induced inflammation
Keywords:acute respiratory infections, acute rhinosinusitis, Enisamium Iodide (nasal spray), Ibuprofen, leukotriene-induced inflammation, anti-inflammatory activity
The use of medicines of the local action with complex effects on the pathogenic cascade of acute rhinosinusitis (ARS) is expedient. Farmak Joint-Stock Company (Ukraine) has developed a new original dosage form of a nasal spray, which contains an aqueous solution of the known pharmaceutical substance Enisamium Iodide (EI). The presence of the effect on the leukotriene link inflammation in EI can determine the high rate of the antiexudative action development in the topical (intranasal) application. This may be useful for pathogenetic therapy of ARS on the background of acute respiratory viral infections taking into account the potential effectiveness for nasal congestion relief.
Aim. To substantiate experimentally the expediency of application of a new nasal spray with EI under conditions of leukotriene-induced exudative inflammation.
Materials and methods. A new nasal spray EI (JSC Farmak (Ukraine)) – “Amizon” – with the active substance concentration of 10 mg/ml was chosen as the study object. Ibuprofen – “Nurofen” (Reckitt Benckiser Helchere International Limited (UK)), film-coated tablets, 200 mg – was used as the reference drug and was administered once daily in the dose of 48 mg/kg intragastrically. The study of anti-inflammatory properties of EI (nasal spray, 10 mg/ml) in the external (epicutaneous) application was performed on white nonlinear rats of both genders in the experimental zymosan-induced inflammation development. The anti-inflammatory activity (AIA) of EI (nasal spray, 10 mg/ml) compared to Ibuprofen was assessed in percentage in dynamics in 0.5, 1 and 2 hours of observation.
Results. According to the results of the studies conducted EI in the dosage form of a nasal spray in the active substance concentration of 10 mg/ml on the model of zymosan-induced inflammation of the rat foot showed the anti-inflammatory properties. According to the degree of its anti-inflammatory properties EI was not inferior to the reference drug Ibuprofen, but even exceeded its activity as of the 30th minute of observation after zymosan injection. The result obtained allows suggesting the presence of high rate of the antiexudative action in the experimental object in the topical (intranasal) application in the treatment of patients with ARS due to the ability to inhibit the lipoxygenase route of the arachidonic acid metabolism.
Conclusions. The presence of the anti-inflammatory activity of Enisamium Iodide (nasal spray) has been proven under conditions of leukotriene-induced inflammation reproduction on the model of the zymosan edema. By expression of the anti-inflammatory action during all periods of observation EI is not inferior to the reference drug Ibuprofen, exceeding the activity of the classical NSAID by 1.5 times as of the 30th minute after the pathology onset. The anti-inflammatory activity of Enisamium Iodide in the dosage form of nasal spray experimentally substantiates the expediency and perspectivity of its further preclinical studies.
Fokkens, W. J., Lund, V. J., Mullol, J., Bachert, C., Alobid, I., Baroody, F., … Wormald, P. J. (2012). EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology Journal, 50(1), 1–12. https://doi.org/10.4193/rhino50e2
Koch, A. K., Klose, P., Lauche, R., Cramer, H., Baasch, J., Dobos, G. J., & Langhorst, J. (2016). A Systematic Review of Phytotherapy for Acute Rhinosinusitis. Complementary Medicine Research, 23(3), 165–169. https://doi.org/10.1159/000447467
Chow, A. W., Benninger, M. S., Brook, I., Brozek, J. L., Goldstein, E. J. C., Hicks, L. A., … File, T. M. (2012). Executive Summary: IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. Clinical Infectious Diseases, 54(8), 72–112. https://doi.org/10.1093/cid/cis370
Nakaz MOZ Ukrainy №85 vid 11.02.2016. (2016). «Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy. Hostryi rynosynusyt». – MOZ Ukrainy.
Nakaz MOZ Ukrainy №921 vid 28.04.2017. (2017). Instruktsiia dlia medychnoho zastosuvannia preparatu «Amizon®». Available at: http://mozdocs.kiev.ua/ likiview.php?id= 31489
Nakaz MOZ Ukrainy №1155 vid 31.10.2016. (2016). Instruktsiia dlia medychnoho zastosuvannia preparatu «Amizonchyk®». Available at: http://mozdocs.kiev.ua/ likiview.php?id=41130
Stefanov, A. V. (2002). Doklinichni doslidzhennia likarskykh zasobiv. Kyiv: «Avitsena», 528.
Zhulay, T. S., Shebeko, S. K., & Zupanets, I. A. (2017). The study of the dose-dependent antiexudative effect of a new anti-inflammatory nasal spray. Klìnìčna farmacìâ, 21(4), 11–16. https://doi.org/10.24959/cphj.17.1446
Nakaz MOZ Ukrainy № 461 vid 12.06.2017. (2017). Instruktsiia dlia medychnoho zastosuvannia preparatu «Nurofien». Available at: http://mozdocs.kiev.ua/likiview.php?id=43903
Sigidin, Ya. A., Shvarts, G. Ya., Arzamastsev, A. P., Liberman, S. S. (1988). Lekarstvennaya terapiya vospalitelnogo protsessa: eksperimentalnaya i klinicheskaya farmakologiya protivovospalitelnyih preparatov. Moscow: Meditsina, 240.
Good Laboratory Practice. (2005). OECD principles and guidance for compliance monitoring.
Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. (2010). Official Journal of the European Union Luxembourg, 276, 33–79.
Zakon Ukrainy №3447-IV vid 21.02.2006 r. zi zminamy «Pro zakhyst tvaryn vid zhorstokoho povodzhennia». (2006). Available at: http://www.president.gov.ua/documents/3447-iv-3976
Lapach, S. N., Chubenko, A. V., Babich, P. N. (2000). Statisticheskie metodyi v mediko-biologicheskih issledovaniyah s ispolzovaniem Excel. Kyiv: Morion, 320.
Rebrova, O. Yu. (2006). Statisticheskiy analiz meditsinskih dannyih. Primenenie paketa prikladnyih programm STATISTICA. Moscow: MediaSfera, 312.
Sergienko, V. I., Bondareva, I. B. (2006). Matematicheskaya statistika v klinicheskih issledovaniyah. Moscow: GEOTAR-Media, 304.
Zupanets, I. A., Zhulai, T. S., Sakharova, T. S., & Andrieieva, O. O. (2017). The significance of selecting phytopreparations for individualized therapy of acute rhinosinusitis. Klìnìčna farmacìâ, 21(4), 52–58. https://doi.org/10.24959/cphj.17.1444
Copyright (c) 2018 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).